Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "RI"

10069 News Found

Godavari Biorefineries secures Japanese patent for antiviral compounds
R&D | March 23, 2026

Godavari Biorefineries secures Japanese patent for antiviral compounds

The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways


Shionogi launches global Phase 2 trial for late-onset Pompe disease treatment
Clinical Trials | March 21, 2026

Shionogi launches global Phase 2 trial for late-onset Pompe disease treatment

Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy


Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes
News | March 21, 2026

Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes

The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India


Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare
News | March 21, 2026

Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare

KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval


Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU
News | March 21, 2026

Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU

These approvals represent a defining moment for people living with classical Hodgkin Lymphoma


Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals
Clinical Trials | March 20, 2026

Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes


Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
R&D | March 20, 2026

Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech

The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology


Glenmark Pharmaceuticals USA launches authorized generic of Savella tablets
News | March 20, 2026

Glenmark Pharmaceuticals USA launches authorized generic of Savella tablets

Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg


Clariant boosts US pharmaceutical production with Clear Lake expansion
News | March 20, 2026

Clariant boosts US pharmaceutical production with Clear Lake expansion

The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production